Journal ArticleDOI
Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response
Fabrizio Fantini,Antonietta Greco,C. Del Giovane,A. M. Cesinaro,Marina Venturini,Cristina Zane,T Surrenti,Ketty Peris,Piergiacomo Calzavara-Pinton +8 more
Reads0
Chats0
TLDR
It is difficult to draw clear‐cut indications to use PDT for treatment of BCC in clinical practice, as scant information is available about the impact of both patient and lesion‐related characteristics on the effectiveness of therapy.Abstract:
Background Photodynamic therapy (PDT) is increasingly used in the treatment of basal cell carcinoma (BCC). However, scant information is available about the impact of both patient- and lesion-related characteristics on the effectiveness of therapy. Therefore, on the basis of the current data, it is difficult to draw clear-cut indications to use PDT for treatment of BCC in clinical practice.
Objective To investigate the clinical and pathological determinants of response of BCC to PDT with methylaminolevulinate (MAL) and red light.
Methods The clinical and pathological characteristics of 194 BCCs in 135 patients, treated with MAL-PDT, were evaluated. Lesions were treated with MAL-PDT according to established methods and the response was assessed by clinical follow-up of the patients.
Results Complete response to PDT was 62%, with a better response for superficial BCC (95/116, 82%) than nodular BCC (26/78, 33%). When determinants of response were analysed, the nodular type and the location on the limbs emerged as significant clinical predictors of failure. Among the pathological characteristics, the nodular and infiltrative histotypes, as well as ulceration and tumour thickness were associated with a lower response to therapy. Patients’ age and gender, as well as the size of the lesions, were not found to be significant predictors.
Conclusions Optimization of PDT procedure for BCC requires a careful selection of the lesions. In particular, superficial BCCs, preferentially located on the trunk, show the best therapeutic response.read more
Citations
More filters
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma.
TL;DR: High efficacy is demonstrated for PDT using standardized protocols in non‐hyperkeratotic actinic keratoses, Bowen’s disease, superficial basal cell carcinomas (BCC) and in certain thin nodular BCC, with superiority of cosmetic outcome over conventional therapies.
Journal Article
Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management.
Alexander Marzuka,Samuel E. Book +1 more
TL;DR: The pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management of BCC will be discussed in this review.
Journal ArticleDOI
Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer
Malgorzata Wachowska,Angelika Muchowicz,Malgorzata Firczuk,Magdalena Gabrysiak,Magdalena Winiarska,Malgorzata Wanczyk,Kamil Bojarczuk,Jakub Golab +7 more
TL;DR: Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT), this is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment.
Journal ArticleDOI
Update of the European guidelines for basal cell carcinoma management
Myrto Trakatelli,Colin A. Morton,Eduardo Nagore,Claas Ulrich,Véronique Del Marmol,Ketty Peris,Nicole Basset-Seguin +6 more
TL;DR: The European guidelines for the management of basal cell carcinoma (BCC) published by the former BCC subcommittee of the Guidelines Committee of the European Dermatology Forum (EDF) were published in 2006.
References
More filters
Journal ArticleDOI
5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.
Qian Peng,Trond Warloe,Kristian Berg,Johan Emelian Moan,Magne Kongshaug,Karl Erik Giercksky,Jahn M. Nesland +6 more
TL;DR: Studies have shown that a higher accumulation of ALA‐derived PpIX in rapidly proliferating cells may provide a biologic rationale for clinical use of ALa‐based PDT and diagnosis, however, no review updating the clinical data has appeared so far.
Journal ArticleDOI
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus
Lasse R. Braathen,Rolf-Markus Szeimies,Nicole Basset-Seguin,Robert Bissonnette,Peter Foley,David M. Pariser,Rik Roelandts,Ann-Marie Wennberg,Colin A. Morton +8 more
TL;DR: Topical photodynamic therapy (PDT) is used to treat nonmelanoma skin cancers, such as actinic keratoses, Bowen's disease, and basal cell carcinoma (superficial and nodular) as mentioned in this paper.
Journal ArticleDOI
Guidelines for topical photodynamic therapy: update.
TL;DR: Multicentre randomized controlled studies now demonstrate high efficacy of topical photodynamic therapy (PDT) for actinic keratoses, Bowen’s disease and superficial basal cell carcinoma, and efficacy in thin nodular BCC, while confirming the superiority of cosmetic outcome over standard therapies.
Journal ArticleDOI
Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?
Peter Wolf,E. Rieger,Helmut Kerl +2 more
TL;DR: Topical photodynamic therapy with endogenous porphyrins is effective for superficial epithelial skin tumors and only 1 of 10 nodulo-ulcerative basal cell carcinomas completely resolved.
Journal ArticleDOI
Interventions for basal cell carcinoma of the skin
TL;DR: Surgery and radiotherapy appear to be the most effective treatments for basal cell carcinoma with surgery showing the lowest failure rates and cosmetic outcomes appear good with PDT, although long term follow up data are needed.
Related Papers (5)
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial
Aimee H.M.M. Arits,Aimee H.M.M. Arits,Klara Mosterd,Klara Mosterd,Brigitte A. B. Essers,Eefje Spoorenberg,Anja Sommer,Anja Sommer,Michette J. M. De Rooij,Han P. A. van Pelt,Patricia J. F. Quaedvlieg,Gertruud A. M. Krekels,Pierre A. F. A. van Neer,Joris J. Rijzewijk,Adrienne J. van Geest,P.M. Steijlen,P.M. Steijlen,Patty J. Nelemans,Nicole W.J. Kelleners-Smeets,Nicole W.J. Kelleners-Smeets +19 more